Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update
Fourth quarter 2024 net revenue from global sales of IMCIVREE® (setmelanotide) of $41.8 million ---- On track to report topline data from ...